NOVEL TCR FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA(鼻咽癌的新式TCR疗法)

THE TECHNOLOGY Reactivated EBVspecific Tcells from a healthy Chinese donor were screened for reactivity to the EBV protein LMP2 restricted by the HLAA*****1101 allele is found in over 50% of the Chinese population [9], ***’s T cells to be reengineered to express the target TCR and tumour antigen within 24 – *** *** ****A1101, ***